If retatrutide is the newest name in incretin research, tirzepatide is the one with the deepest published record behind it. It sits at the center of the metabolic literature of the last five years, and it is the compound most researchers reach for when they want a dual-agonist reference point.
What tirzepatide is
Tirzepatide is a synthetic peptide that the literature characterizes as a dual agonist: it engages both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. That two-receptor profile distinguishes it from single-target GLP-1 agonists like semaglutide and from the triple agonist retatrutide, and it is the reason comparative incretin studies almost always include it.
Where the evidence stands
Tirzepatide is unusual in this catalog for how far its clinical record extends: pharmaceutical forms of the molecule are approved drugs, developed through large published clinical programs in type 2 diabetes and weight management. That published human evidence base is exactly why the compound is so heavily cited and why laboratories continue to study its receptor pharmacology and downstream signaling.
The distinction that matters here: research-grade tirzepatide is not a pharmaceutical product. It is not manufactured or regulated as a drug, and it is sold strictly for laboratory and in-vitro research. The shared molecule name does not make the categories interchangeable.
What laboratories study
Published laboratory work around tirzepatide centers on GIP and GLP-1 receptor binding and activation, comparative signaling against single agonists, and its behavior in cell-based and animal models of metabolism. It also serves as an analytical reference compound for labs verifying incretin-class peptides by chromatography and mass spectrometry.
In our catalog
We stock Tirzepatide (20mg) as a lyophilized research compound. The product page lists its CAS number, molecular formula, and molecular weight, and the vial ships with a printed lot number you can match against our public COA ledger. Lots still in third-party testing are labeled pending; we do not publish results we do not have.
Quick answers
How is tirzepatide different from semaglutide? Semaglutide is described as a single GLP-1 receptor agonist; tirzepatide engages GIP and GLP-1 receptors together.
Is research-grade tirzepatide the same as the branded drugs? No. Research-grade material is not a pharmaceutical product and is a laboratory material only.
How do I verify a lot? Match the lot number printed on the label to its entry in the COA ledger.
For laboratory and in-vitro research use only.
For laboratory and in-vitro research use only. Not for human or veterinary use. See our research-use disclaimer.
